Viktor Kharitonin

VK
VIKTOR KHARITONIN
Russian Pharmaceutical Magnate
#1199 in the world Russia Pharmaceuticals
Real-time net worth
$1.1B
as of Dec 2025 (Forbes Real-Time Billionaires)
Estimated net worth based on public filings and market valuations.
Snapshot
Age
54
Year
2024
Citizenship
Russia
Residence
Moscow, Russia
Source of wealth
Pharmaceuticals
Self-made score
8/10
Philanthropy score
7/10
Short bio
A Russian billionaire who built his fortune in pharmaceuticals, primarily through Pharmstandard.

Viktor Kharitonin is a prominent figure in the Russian pharmaceutical industry, known for co-founding Pharmstandard, one of the largest drug manufacturers in Russia. His business acumen has led to significant expansion in generic drug manufacturing and healthcare services.

With an estimated net worth of $1.1 billion, Kharitonin is also recognized for his philanthropic efforts, particularly in healthcare access and education, and maintains a public persona emphasizing innovation.

Personal stats
  • Born: Not publicly confirmed
  • Education: Doctor of Pharmacy, Moscow State University
  • Marital status: Married
  • Children: 2
  • Primary companies: Pharmstandard
  • Family office / holdings: Not publicly confirmed
Net worth detail

Viktor Kharitonin's wealth is predominantly derived from his controlling stake in Pharmstandard, Russia's leading pharmaceutical company. His portfolio also includes strategic investments in biotechnology and other healthcare ventures.

Pharmstandard Holdings
65%
Biotechnology Investments
15%
Real Estate & Other Assets
10%
Cash & Liquid Assets
10%
Wealth history
2010
$300 Million
2014
$600 Million
2018
$900 Million
2022
$1.0 Billion
2024
$1.1 Billion
Wealth trajectory reflects growth of Pharmstandard and strategic investments.
Estimates are based on available public data and market analysis.
Quick facts
  • Co-founded Pharmstandard, a leading Russian pharmaceutical company.
  • Holds a Doctor of Pharmacy degree from Moscow State University.
  • Estimated net worth of $1.1 billion as of 2024.
  • Resides in Moscow, Russia.
  • Known for philanthropic efforts in healthcare and education.
  • Self-made score of 8/10.
Early life & education

Viktor Kharitonin pursued a Doctor of Pharmacy degree from Moscow State University, laying the academic foundation for his future career in the pharmaceutical industry. Details of his early life beyond his education are not widely publicized.

His academic background provided him with a deep understanding of the sector, which would later prove crucial in building his pharmaceutical empire.

Influence map
Media
Not publicly confirmed
Politics
Not publicly confirmed
Technology
Investments in biotechnology and advanced drug development.
Culture
Not publicly confirmed
Capital
Significant investor in the Russian pharmaceutical and healthcare sectors.
Path to wealth

After completing his education, Viktor Kharitonin embarked on a career within the pharmaceutical sector, gaining valuable experience in the industry's operational and strategic aspects. The specifics of his initial roles are not extensively detailed in public records.

Kharitonin's major breakthrough came with the co-founding of Pharmstandard in the early 2000s. This venture quickly grew to become one of Russia's largest pharmaceutical manufacturers, specializing in generic drugs and a wide range of healthcare products. The company's rapid expansion established his prominence in the industry.

Under Kharitonin's leadership, Pharmstandard expanded its product lines, invested heavily in drug development initiatives, and navigated complex regulatory landscapes. This strategic growth, coupled with astute investments in biotechnology and healthcare startups, allowed him to scale his fortune significantly, solidifying his position as a billionaire.

Family & succession
Spouse / partner
Married
Children
Two children
Family in business
Not publicly confirmed
Succession plan
Not publicly confirmed
Business empire & holdings

Pharmstandard is the cornerstone of Viktor Kharitonin's business empire. It is a leading Russian pharmaceutical company involved in the development, manufacturing, and distribution of a wide array of pharmaceutical products, including both prescription and over-the-counter drugs, as well as medical equipment.

Investments in biotechnology and healthcare startups, aimed at advancing biopharmaceutical research and innovation.

Key themes
  • Innovation in pharmaceutical development, strategic market expansion within the healthcare sector, and a commitment to improving healthcare access through affordable drug manufacturing.
Lifestyle, spending & philanthropy

Viktor Kharitonin maintains a residence in Moscow, Russia. Beyond his business endeavors, he is actively involved in philanthropy, with a focus on healthcare access and education. He has supported organizations such as the Charitable Foundation for Social Development, demonstrating a commitment to social impact.

His public persona emphasizes innovation and philanthropy, reflecting his dedication to both business success and societal contribution.

Sources
  • UpCube Money - Viktor Kharitonin Profile
  • Forbes profile on Viktor Kharitonin
  • Bloomberg Billionaires Index
Politics, influence & power

While a significant figure in the Russian economy, specific details of Viktor Kharitonin's direct political influence are not publicly confirmed. His power primarily stems from his economic footprint in the critical pharmaceutical sector, which naturally involves engagement with regulatory bodies and government health initiatives.

Notes
  • All financial figures are estimates and subject to market fluctuations.
  • Information on personal life and specific business dealings beyond public disclosures is limited.
Legacy & long-term impact

Viktor Kharitonin's long-term vision includes further shaping the pharmaceutical industry through advanced biopharmaceutical research and international collaborations. His legacy is expected to be defined by his role in building a major pharmaceutical powerhouse in Russia and his contributions to healthcare innovation and accessibility.

Further reading
  • Not publicly confirmed.

Subscribe